SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

elebsiran

VIR·Vir Biotechnology, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Phase 3
Time to market
If Phase 3 ECLIPSE 1 results are positive, regulatory filings could follow in 2027, with potential FDA approval in 2027-2028 given the Breakthrough Therapy designation enabling expedited review.
Why 8/10
The next hard, dated catalyst is the presentation of topline primary endpoint results from the pivotal Phase 3 ECLIPSE 1 trial at AASLD The Liver Meeting 2026 on November 8, 2026, with an investor call on November 9. This is a binary readout on the company's lead program driving most of the investment thesis, occurring within days.
Actionable Insight BULLISH

The pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.

Price Chart

Loading chart...

Executive Summary

Elebsiran (VIR-2218) is an investigational siRNA therapy from Vir Biotechnology (Nasdaq: VIR) being developed in combination with tobevibart for chronic hepatitis delta (CHD) and hepatitis B. The pivotal Phase 3 ECLIPSE 1 trial topline results are being presented at AASLD on November 8, 2026, representing the most important binary catalyst for the company. The combination has FDA Breakthrough Therapy and EMA PRIME designations, and Vir has a commercial licensing deal with Norgine worth up to ~$645M for Europe, Australia and New Zealand. The stock trades at ~$12 with a Strong Buy analyst consensus and a mean price target of $21 (~91% upside), supported by $901M cash runway into H2 2028. Competition includes bulevirtide (Hepcludex), which was FDA-approved in May 2026.

How It Works

Elebsiran is a small interfering RNA (siRNA) drug that works by entering liver cells and destroying the genetic instructions (RNA) that the hepatitis B and delta viruses use to make surface antigen proteins. By reducing these proteins, it aims to break the virus life cycle and allow the immune system to clear the infection. It is injected under the skin and uses a sugar molecule (GalNAc) to target delivery specifically to liver cells.

Trial Status

The pivotal Phase 3 ECLIPSE 1 trial (NCT06903338) evaluating elebsiran plus tobevibart in chronic hepatitis delta has completed enrollment and topline primary endpoint results are being presented at AASLD on November 8, 2026. Two additional Phase 3 trials are active: ECLIPSE 2 (evaluating switch from bulevirtide) and a head-to-head Phase 2/3 ECLIPSE 3 versus bulevirtide. Phase 2 SOLSTICE data showed high rates of undetectable HDV RNA and durable suppression through 96 weeks, published in NEJM. For hepatitis B, the Phase 2 MARCH study is evaluating elebsiran with tobevibart +/- pegylated interferon.

The Two-Sided Case

▲ Bull Case6
Elebsiran plus tobevibart has FDA Breakthrough Therapy Designation and EMA PRIME Designation for chronic hepatitis delta, enabling expedited regulatory review.
Phase 2 SOLSTICE data showed high rates of undetectable HDV RNA and ALT normalization, with durable 96-week suppression published in NEJM.
The Norgine licensing deal (up to ~$645M) validates the program and provides a commercial partner for Europe, Australia and New Zealand.
Analyst consensus is Strong Buy (12 analysts: 4 strong buy, 8 buy, 1 hold) with a mean price target of $21, implying ~91% upside from the $11.02 close.
Cash runway into H2 2028 ($901M) eliminates near-term financing risk, and the Gilead collaboration adds further non-dilutive support.
Multiple tracked institutional investors added or doubled positions in Q2 2026, including Point72 (+190%), State Street (+39.5%), and Nuveen (+94.6%).
▼ Bear Case6
Bulevirtide (Hepcludex) was FDA-approved in May 2026 for chronic hepatitis delta, establishing a competitive benchmark that elebsiran/tobevibart must beat or match.
The Phase 3 ECLIPSE 1 trial is open-label (not blinded), which can introduce bias and may limit the strength of the evidence for regulators.
Multiple institutional investors trimmed or exited positions in Q2 2026, including Citadel (-52.8%), Millennium (-90.2%), and Jacobs Levy (-90.5%), signaling skepticism.
Elevated short-sale volume (z-score 2.02 vs own history) suggests bearish positioning ahead of the readout.
The company remains pre-revenue with negative EPS (-$0.57 in Q3 2026), and the Norgine deal, while providing non-dilutive funding, caps European upside at milestones.
Elebsiran is also partnered with Brii Biosciences for HBV in China, creating potential complexity in rights and economics.

Upcoming Catalysts

  • November 8, 2026: Late-breaking oral presentation of Phase 3 ECLIPSE 1 topline primary endpoint results at AASLD The Liver Meeting 2026
  • November 8, 2026: Expanded Phase 2 SOLSTICE data presentations at AASLD
  • November 9, 2026: Investor conference call to discuss ECLIPSE 1 and SOLSTICE results
  • Q1 2027: Expected topline data from ECLIPSE 2 and ECLIPSE 3 trials
  • 2027: Potential regulatory submissions for CHD if ECLIPSE 1 is positive

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vir Biotechnology, Inc. 8-K VIR ·Originating report

Sources · 10

Hover a chip for the title
1 investors.vir.bio2 businesswire.com3 norgine.com4 investors.vir.bio5 investors.vir.bio6 nejm.org7 briibio.com8 stockanalysis.com9 stockanalysis.com10 hepb.org